Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 47.5 mg - tablet, modified release - excipient ingredients: magnesium stearate; ethylcellulose; glycerol; microcrystalline cellulose; stearic acid; hypromellose; titanium dioxide; maize starch; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: titanium dioxide; glycerol; magnesium stearate; microcrystalline cellulose; stearic acid; ethylcellulose; maize starch; hypromellose; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - desvenlafaxine succinate monohydrate, quantity: 151.77 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: purified talc; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - pristiq is indicated for the treatment of major depressive disorder, including the prevention of relapse. pristiq is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - desvenlafaxine succinate monohydrate, quantity: 75.87 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; purified talc; microcrystalline cellulose; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - pristiq is indicated for the treatment of major depressive disorder, including the prevention of relapse. pristiq is not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - methylprednisolone sodium succinate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - methylprednisolone sodium succinate -

United States - English - NLM (National Library of Medicine)

par pharmaceutical - frovatriptan succinate (unii: d28j6w18hy) (frovatriptan - unii:h82q2d5wa7) - frovatriptan 2.5 mg - frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use - use only if a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. use only if a clear diagnosis of migraine has been established. if a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. - frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache. safety an

United States - English - NLM (National Library of Medicine)

cambridge therapeutics technologies, llc - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 100 mg - 1.1 hypertension metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - methylprednisolone sodium succinate, quantity: 1326 mg (equivalent: methylprednisolone, qty 1000 mg) - injection, powder for - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate dihydrate - when oral therapy is not feasible & strength, dosage form & route of administration of drug reasonably lend preparation to treatment of following conditions. intravenous or intramuscular use only.,endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is drug of choice; mineralocorticoid supplementation may be necessary particularly when synthetic analogues are used). preoperatively & in event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or suspected, congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcaemia associated with cancer. congenital adrenal hy